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Abstract
Background: Bacterial meningitis (BM) is an infectious disease that results in high mortality and morbidity. Despite
efficacious antibiotic therapy, neurological sequelae are often observed in patients after disease. Currently, the main
challenge in BM treatment is to develop adjuvant therapies that reduce the occurrence of sequelae. In recent
papers published by our group, we described the associations between the single nucleotide polymorphisms
(SNPs) AADAT +401C > T, APEX1 Asn148Glu, OGG1 Ser326Cys and PARP1 Val762Ala and BM. In this study, we
analyzed the associations between the SNPs TNF -308G > A, TNF -857C > T, IL-8 -251A > T and BM and investigated
gene-gene interactions, including the SNPs that we published previously.
Methods: The study was conducted with 54 BM patients and 110 healthy volunteers (as the control group). The
genotypes were investigated via primer-introduced restriction analysis-polymerase chain reaction (PIRA-PCR) or
polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis. Allelic and
genotypic frequencies were also associated with cytokine and chemokine levels, as measured with the x-MAP
method, and cell counts. We analyzed gene-gene interactions among SNPs using the generalized multifactor
dimensionality reduction (GMDR) method.
Results: We did not find significant association between the SNPs TNF -857C > T and IL-8 -251A > T and the disease.
However, a higher frequency of the variant allele TNF -308A was observed in the control group, associated with
changes in cytokine levels compared to individuals with wild type genotypes, suggesting a possible protective role.
In addition, combined inter-gene interaction analysis indicated a significant association between certain genotypes
and BM, mainly involving the alleles APEX1 148Glu, IL8 -251 T and AADAT +401 T. These genotypic combinations
were shown to affect cyto/chemokine levels and cell counts in CSF samples from BM patients.
Conclusions: In conclusion, this study revealed a significant association between genetic variability and altered
inflammatory responses, involving important pathways that are activated during BM. This knowledge may be useful
for a better understanding of BM pathogenesis and the development of new therapeutic approaches.
Background
Despite immunization programs and effective antimicro-
bial therapies against bacterial meningitis (BM), the inci-
dences of mortality and neurological sequelae caused by
this disease remain high [1]. A complex series of events
involving host cytokines, chemokines, proteolytic en-
zymes and oxidizing agents appear to be responsible for
the occurrence of brain damage during BM. This re-
sponse depends not only on the type and intensity of the
stimulation but also on host genetic factors, such as gen-
etic polymorphisms located in coding or regulatory re-
gions of key genes [2–4].
BM is characterized by an acute inflammatory re-
sponse that is initiated by the presence of bacterial path-
ogens in the central nervous system (CNS). The disease
begins with nasopharyngeal colonization by the patho-
gen and subsequent invasion of the bloodstream. During
this phase, BM can be avoided with efficient innate and
acquired immune responses [2, 4].
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Several bacterial species that are pathogenic to humans
have the potential to cause meningitis, but a relatively
small number of pathogens, as Haemophilus influenzae
type b [Hib], Streptococcus pneumoniae and Neisseria
meningitides, are responsible for the majority of acute BM
cases [5, 6]. These primary pathogens utilize distinct but
overlapping sets of Toll-like receptors (TLRs) to trigger
the inflammatory response, inducing NF-κB activation in
a MyD88-dependent pathway [7–9]. Corroborating these
data, in a recent study published by our group, we ob-
served a similar profile of cytokine expression during
pneumococcal and meningococcal meningitis [10]. Tumor
necrosis factor (TNF-α), IL-1β and IL-6 are the major
early response cytokines that trigger a cascade of
inflammatory mediators, including other cytokines,
chemotactic cytokines (chemokines) such as CXCL8/
IL-8, MIP-1α/CCL3, MIP-1β/CCL4, MCP-1/CCL2,
prostaglandins, matrix metalloproteinases (MMPs), re-
active oxygen species (ROS) and reactive nitrogen inter-
mediates (RNI) [2, 9, 11].
In previous studies, we described the associations be-
tween BM and the single nucleotide polymorphisms
(SNPs) AADAT +401C > T (rs1480544) [12], APEX1
Asn148Glu (rs1130409), OGG1 Ser326Cys (rs1052133)
and PARP1 Val762Ala (rs1136410) [13]. The AADAT
gene encodes the enzyme kynurenine aminotransferase
II, which is involved in the kynurenine (KYN) pathway,
the major route for tryptophan degradation in the brain.
Alterations in this pathway are associated with several
diseases that compromise the CNS [14]. APEX1, OGG1
and PARP1 encode DNA repair enzymes involved in the
base excision repair (BER) pathway, one of the most im-
portant pathways for the repair of oxidized DNA dam-
age in neurons [15].
In this study, we analyzed the associations between the
SNPs TNF -308G > A (rs1800629), TNF -857C > T
(rs1799724), and IL8 -251A > T (rs4073) and BM. In
addition, we also investigated gene-gene interactions, in-
cluding the SNPs previously investigated by our group
[12, 13]. The SNPs TNF -308G > A and TNF - 857C > T
are localized in the regulatory region of the TNF pro-
moter and were described to be involved in increased
transcriptional activity of the TNF gene [16–18].
CXCL8/IL-8 is involved in the chemotactic activity of
polymorphonuclear and mononuclear cells. The genetic
polymorphisms IL8 -251A > T causes decreased expres-
sion of this chemokine [19–21].
Although several molecular markers have become
areas of focus for research, few studies have considered
the interplay between markers. In this study, we investi-
gated genetic association data from a model for suscepti-
bility to BM that integrated important routes that are
activated during the disease. Our findings demonstrated
a higher frequency of variant allele TNF -308A in the
control group, suggesting a possible protective role
against disease, and genetic combinations, primarily in-
volving the alleles TNF -308G, APEX1 148Glu, IL8
-251T and AADAT +401T, that were associated with the
occurrence of BM.
Methods
Ethics statement
This work was approved by the Brazilian Ethics Com-
mittee (CONEP, CAAE 0052.1.051.000-05). All subjects
signed the informed consent agreeing to participate in
this research. In the case of minors/child participants in-
volved in this study, we obtained informed written con-
sent from the legal guardians.
Study population and samples
The study was conducted with a group of 54 patients (35
men and 19 women), 21 individuals were 18 years or
younger, 25 aged from 18 to 60 years, 4 individuals aged
over 60 years, and 4 with unknown age. The patients were
admitted in the Hospital Giselda Trigueiro (HGT), Natal-
RN, Brazil, which is a reference hospital for infectious dis-
eases in the state. BM diagnosis was based on the hospital
routine, which includes: (1) positive CSF bacterial culture,
(2) detection of the pathogen in the CSF by Gram staining
plus clinical signs (acute onset, fever, meningeal irritation)
and/or (3) positive blood culture or Gram stain in the
presence of clinical signs of meningitis, (4) positive bacter-
ial antigen detection in the CSF or blood using the latex
agglutination test, with clinical signs of meningitis, (5)
CSF parameters including increased protein content
(>40 mg/dL), reduced glucose levels (<40 mg/dL) and the
presence of CSF pleocytosis (≥500 cells/mm3), with pre-
dominantly polymorphonuclear granulocytes (PMN), and
(6) symptoms such as high fever, chills, severe headache,
nausea and vomiting, and the Kernig and Brudzinski signs
of meningo-radicular syndrome. However, some patients
with clinical manifestations of bacterial meningitis were
on antibiotic treatment prior to definitive diagnosis, so it
was not possible to define accurately the etiologic agent.
These patients were used only for genotypes analysis and
excluded from the inflammatory markers analysis. More-
over, patients undergoing chronic treatment with anti-
inflammatory or with other diseases (such as AIDS) that
affect the immune and inflammatory responses (e.g., cyto-
kine expression) were excluded from the study. Healthy
volunteers and patients attended at the HGT, who had a
negative diagnosis for infectious disease, were included in
the study as part of the control group, a total of 110
samples (53 men and 57 women), 10 individuals were
18 years or younger, 99 individuals aged from 18 to
60 years and 1 individuals aged over 60 years. These pa-
tients were used as controls given that no infection was
confirmed and all parameters for diagnosis were normal.
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In healthy volunteers, CSF samples were not collected, as
lumbar puncture is a very invasive method, but a ques-
tionnaire evaluating the history of infectious and inflam-
matory diseases was administered to the healthy
volunteers. In addition, blood samples were submitted to
obtain white blood cell counts (WBC) and differentials,
cytokines and chemokines were analyzed, and it was de-
termined whether the individual had a fever at the time of
collection of the biological sample. In relation to BM, 54
patients had a positive diagnosis: 17 were diagnosed with
S. pneumonia; 7 with N. meningitides; 6 with other patho-
gens; and 24 without a specified etiology. CSF biochemical
parameters of each causative agent are shown in Table 1
(more detail can be found in [10] and [22]).
Sample collection and processing
Blood samples were collected and processed by centrifu-
gation at 2,880 g and 4 °C for 3 min to separate the
plasma. Genomic DNA extraction was performed using
the salting out procedure following the protocol de-
scribed by Miller et al. [23]. Samples of CSF were col-
lected upon lumbar puncture (LP) and centrifuged at
720 g for 5 min. Supernatants were frozen and stored at
−80 °C before any further procedure. Blood samples
were obtained from all patients and volunteers. However,
given that LP is a very invasive procedure, CSF samples
were obtained only from patients undergoing procedures
for the diagnosis of meningitis. Patients who had a posi-
tive diagnosis were included in the BM group.
Genotypic analysis
The SNPs investigated in this study are detailed in Table 2.
The primer sequences for TNF -308G >A, TNF -857C >
T, and IL8 -251A > T have been previously described [24–
26]. Primer-introduced restriction analysis-polymerase
chain reaction (PIRA-PCR) was carried out to identify the
SNP TNF -308G >A, containing a single-base mismatch
leading to the amplification of PCR products containing a
restriction site. For all SNPs, genotyping was performed
following the digestion of the amplified fragments with
appropriate restriction endonucleases using the method-
ology for restriction fragment length polymorphism (PCR-
RFLP) (Table 3). PCR was carried out using 100 ng of
genomic DNA in a 25-μl volume reaction containing 1X
specific buffer, 10 pM of each primer, 2.0 mM MgCl2, 0.3
mMol of each dNTP, and 3.6 U of Taq polymerase. The
PCR conditions were as follows: initial denaturation at
94 °C for 5 min, followed by 35 cycles of 45 s at 94 °C for
denaturation and annealing for 45 s (temperatures given
in Table 3), elongation at 72 °C for 1 min, and a final ex-
tension step at 72 °C for 5 min. PCR products were run
on 2 % agarose gels and visualized with ethidium bromide.
The digestion of PCR products was performed following
the instructions of the manufacturers of the restriction en-
zymes. The digestion products were analyzed on an 8 %
polyacrylamide gel and were revealed with silver staining
according to the protocol described by Sanguinetti et al.
[27]. Quality control was carried out with 20 % repetition
of the entire sample for each SNP to evaluate data
reproducibility.
Cytokine multiplex measurements in CSF and plasma
Proinflammatory cytokine and chemokine levels in the
CSF and plasma were measured during the acute phase
of disease and before the start of treatment with antibi-
otics. Analysis was performed with microsphere-based
multiplex assays (xMAP Luminex technology) using the
Bio-Plex 200 suspension array system (Bio-Rad, Hercules,
CA, USA). A human cytokine Lincoplex Kit (HCYTO-
60 k, Millipore, Billerica, Ma, USA) was used to analyze a
set of 12 cytokines and chemokines (TNF-α, IL-6, IL-1β,
INF-γ, IL-2, IL-10, IL-1RA, MIP-1α/CCL3, MIP-1β/CCL4,
MCP-1/CCL2, G-CSF and IL-8/CXCL8). The samples
were processed and measured according to the manufac-
turer’s instructions, as described previously [10, 12, 13].
Cyto/chemokine expression was measured in duplicate,
and the inflammatory modulators levels were analyzed in
relation to a parametric logistic curve using Bio-Plex man-
ager 4.01 software and expressed as pg/ml. Due to the low
quantities of biological material, evaluation of all patients
was not possible.
Statistical analysis
Allelic and genotypic frequencies were calculated for pa-
tient and control subjects via direct gene counting.
Hardy-Weinberg equilibrium was evaluated using GEN-
EPOP 4.2 software (http://genepop.curtin.edu.au/). For
linkage disequilibrium analysis (LD) of the TNF -308G >
A and TNF -857C > T polymorphisms, Haploview soft-
ware version 4.2 was used as described previous [28].
Table 1 CSF biochemical parameters of BM meningitis etiologies
CSF (n samples) Age (years) Cell count (cells/mm3) Protein (mg/dL) Glucose (mg/dl)
S. pneumonia (17) 27 (11; 43) 1,960 (698;8 3,730) 198.00 (137.50; 339,00) 17 (4; 26.70)
N. meningitides (7) 21 (6; 27) 1,120 (3,440; 14,400) 177.0 (88.00; 314.00) 7.3 (2; 47.90)
Other pathogens (6) 7 (1; 15) 3,083 (1,835; 5,998) 218.5 (174.00; 317.80) 4.1 (0; 29.25)
Unknown etiology (24) 22 (6; 46) 505 (159; 1490) 78.20 (35.00; 1350.00) 51,60 (45.10; 70.00)
Values are represented as medians (25; 75 percentiles)
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Logistic regression analyses were used to calculate odds
ratios (OR), 95 % confidence intervals (CI) and corre-
sponding P-values to determine the association between
each variant and susceptibility to BM. In this analysis,
the effects of age and sex were evaluated. STATA soft-
ware (version 11.0; Stat Corporation, College Station,
Texas, USA) was used to conduct this statistical analysis.
The generalized multifactor dimensionality reduction
(GMDR) analysis was used to assess gene–gene interac-
tions with GMDR Beta 0.9 software. This method has
been shown to be effective for detecting gene-gene inter-
actions in case–control studies with relatively small sam-
ple sizes. The best statistical gene–gene interactions
model for a given order of interaction was determined
by three factors: the cross-validation consistency statis-
tics for the selected SNP combinations, the prediction
accuracies and the significance level or P-value, for
which all possible interactions were tested 10 times in
an exhaustive search [29, 30]. A total of 1,000 permuta-
tion tests were performed in each analysis. For statistical
analysis, we used the autosomal dominant model (Aa +
aa vs. AA) wherein the presence of the “a” allele is suffi-
cient to show the phenotype. In addition, differences in
levels of inflammatory modulators were analyzed using
GraphPad Prism5 software. It was used the non-
parametric Mann–Whitney U test, for comparisons
between two groups, and Kruskal-Wallys test followed
by Dunn's Multiple Comparison post-test. For the cor-
relation analysis, it was used the Spearman test.. Values
of P < 0.05 (two-tailed) were considered statistically
significant.
Results
Genotypic frequency analysis
The distribution of the genotypic frequencies of the TNF
-308G > A, TNF -857C > T, and IL8 -251A > T polymor-
phisms in BM patients and controls are shown in
Table 4. All genotypic distributions were in Hardy-
Weinberg equilibrium (Additional file 1: Table S1).
Haplotype analysis indicated a D’ value of 0.11 for the
TNF polymorphisms -308G > A and -857C > T, suggest-
ing that they segregate independently (Additional file 1:
Figure S1). No significant differences between the BM
and control groups were found in relation to the SNPs
TNF -857C > T and IL8 -251A > T. However, in the
multivariate regression model, an association between
the SNP TNF -308G > A and a possible protective role
against BM was observed; even after adjustment for age
and sex, the comparison remained statistically significant
(P = 0.020 and P adjusted = 0.030). Individuals carrying
the GA genotype demonstrated a significant reduction
for BM risk compared to those carrying the GG geno-
type (OR = 0.292 and 95 % CI = 0.12–0.711). Individuals
carrying the AA genotype had an OR of 0.375 compared
with carriers of the GG genotype (95 % CI = 0.041–
0.711). The frequency of the variant allele was decreased
in the BM group (0.08) compared to the control group
(0.18). Of a total of 163 individuals genotyped for the
SNP TNF -308G > A, 70 % were homozygous for the
wild type allele, 26 % were heterozygous, and 4 % were
homozygous for the variant allele.
The individual allelic and genotypic frequencies for the
SNPs AADAT +401C > T, APEX1 Asn148Glu, OGG1
Table 2 Polymorphisms analyzed in this study
Polymorphism Reference Chromosome Functional position Wild type/rare allele
TNF -308G > A rs1800629 6 promoter region G/A
TNF -857C > T rs1799724 6 promoter region C/T
IL8 -251A > T rs4073 4 promoter region A/T
APEX1 Asn148Glu rs1130409 14 exon G/T
OGG1 Ser326Cys rs1052133 3 exon C/G
PARP1 Val762Ala rs1136410 1 exon T/C
AADAT +401C > T rs1480544 4 splice site C/T
Table 3 PCR conditions for genotyping: primer sequences, annealing temperatures and restrictions enzymes
SNP Primer sequence Annealing temperature Restriction enzyme
TNF -308G > A F 5’AGGCAATAGGTTTTGAGGGCCAT'3 55 °C NcoI
R 5’TCCTCCCTGCTCCGATTCCG'3
TNF -857C > T F 5’GGCTCTGAGGAATGGGTTAC'3 58 °C TaiI
R 5’CCTCTACATGGCCCTGTCTAC'3
IL8 -251A > T F 5’CCATCATGATAGCATCTGTA'3 53 °C AseI
R 5’CCACAATTTGGTGAATTATTAA'3
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Ser326Cys and PARP1 Val762Ala were previously pub-
lished [12, 13].
Gene-gene interaction analysis
To identify possible combinations of genotypes that could
affect the occurrence of the disease, we performed an ana-
lysis of gene-gene interactions for each polymorphism.
According to the GMDR data, four different combination
models were obtained, which suggested the best models
for the combination of all SNPs that exhibited associations
with BM (Table 5). We determined the best interaction
models based on a cross-validation of >7 of 10, a predic-
tion accuracy >55 % and a P-value <0.05 for each model.
The combinations of APEX1 Glu/_, AADAT T/_ (P =
0.0107), IL8 T/_, APEX1 Glu/_, AADAT T/_ (P = 0.0010),
IL8 T/_, APEX1 Glu/_, OGG1 Cys/_, PARP1 Ala/_, and
AADAT T/_ (P = 0.0107) were statistically significant, sug-
gesting the variants together may contribute to the occur-
rence of disease. The combination of the three variant
alleles of the DNA repair enzymes was also more frequent
in the BM group, although it was not statistically signifi-
cant (P = 0.0547), but the best combination was the two-
Table 4 Genotypic frequencies of the SNPs for BM compared with the control group
Genotypes and alleles Control group n (%) BM group n (%) P for difference OR (95 % CI) Adjusted P for differencea Adjusted OR (95 % CI) a
TNF −308 (controls = 109; cases = 54)
GG 69 (63) 46 (85) 0.020* 1 0.030* 1
GA 36 (33) 7 (13) 0.292 (0.12-0.711) 0.319 (0.129-0.790)
AA 4 (4) 1 (2) 0.375 (0.041-0.711) 0.311 (0.033-2.943)
TNF −857 (controls = 107; cases = 52)
CC 81 (76) 39 (75) 0.92 1 0.92 1
CT 26 (24) 13 (25) 1.038 (0.482-2.237) 1.475 (0.475-2.290)
TT 0 (0) 0 (0)
IL8 -251 (controls = 106; cases = 52)
AA 31 (29) 12 (23) 0.62 1 0.68 1
AT 43 (41) 25 (48) 1.502 (0.656-3.44) 1.398 (0.596-3.280)
TT 32 (30) 15 (29) 1.211 (0.490-3.00) 1.058 (0.416-2.690)
BM bacterial meningitis, OR odds ratio, CI confidence interval. Data analyzed by multivariate logistic regression analyses. *Statistical significance (P < 0.05). The
reference group in each of the analyses was the most prevalent genotype. aData adjusted for age and gender
Table 5 GMDR results of multi-locus interaction with BM compared with the control group
Best model (All susceptibility SNPs) Testing balanced accuracy Sign test (P-value) Cross-validation accuracy
AADAT T/_ 0.6305 9 (0.0107)* 9/10
APEX1 Glu/_, AADAT T/_ 0.6359 9 (0.0107)* 9/10
IL8 T/_,APEX1 Glu/_, AADAT T/_ 0.6586 10 (0.0010)* 10/10
IL8 T/_,APEX1 Glu/_, OGG1 Cys/_, AADAT T/_ 0.5743 6 (0.3770) 6/10
IL8 T/_,APEX1 Glu/_, OGG1 Cys/_, PARP1 Ala/_,AADAT T/_ 0.6302 9 (0.0107)* 10/10
Best model (DNA repair enzymes) Testing balanced accuracy Sign test (P-value) Cross-validation accuracy
APEX1 Glu/_ 0.6605 9 (0.0107)* 10/10
APEX1 Glu/_, OGG1 Cys/_, 0.5850 9 (0.0107)* 8/10
APEX1 Glu/_, OGG1 Cys/_, PARP1 Ala/_, 0.6510 8 (0.0547) 10/10
Best model (protection SNPs) Testing balanced accuracy Sign test (P-value) Cross-validation accuracy
TNF-308 A/_ 0.5939 9 (0.0107)* 10/10
TNF-308 A/_, TNF-857 T_ 0.5758 8 (0.0547) 10/10
Best model (susceptibility alleles) Testing balanced accuracy Sign test (P-value) Cross-validation accuracy
TNF-308 GG, AADAT T/_ 0.6267 8 (0.0547) 7/10
TNF-308 GG, AADAT T/_, APEX1 Glu/_,IL8 T/_, 0.6108 9 (0.0107)* 7/10
TNF-308 GG, AADAT T/_, APEX1 Glu/_, IL8 T/_, OGG1 Cys/_ 0.5528 7 (0.1719) 5/10
TNF-308 GG, AADAT T/_, APEX1 Glu/_, IL8 T/_, OGG1 Cys/_, PARP1 Ala/_, 0.5553 7 (0.1719) 10/10
*Significant P-value (P < 0.05); P-value was based on 1,000 permutations. Dominant inheritance model (Aa + aa vs. AA)
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locus model with APEX1 Glu/_ and OGG1 Cys/_ (P =
0.0107). Regarding phenotypes that conferred susceptibil-
ity to BM, the best gene-gene interaction model was the
wild type genotype of TNF -308G/G with APEX1 Glu/,
IL8 -251 T/_ and AADAT +401 T/_ (P = 0.0107).
In addition, although isolated effects of the SNP TNF
-857C > T were not observed, the combination of both
variants of the TNF gene resulted in marginal signifi-
cance (P = 0.0547) in terms of the protection against the
disease. Together, the data obtained reveal possible asso-
ciations between different genes that may interact with
each other, leading to the occurrence of BM.
Association of SNPs with immune response markers
In the analysis of cyto/chemokines in relation to individ-
ual genotypes, we observed some significant changes be-
tween the BM and control groups for the SNP TNF
-308G > A alone. An increase in TNF-α and IL-6 levels
was observed in CSF samples from BM patients carrying
the polymorphic TNF -308A allele (Fig. 1a), while an in-
crease in TNF-α and MCP-1 was observed in plasma
samples from the control group (Fig. 1b). The SNP TNF
-308G > A did not exert an effect on other inflammatory
modulators (Additional file 1: Figure S2). For the SNPs
TNF - 857C > T and IL8 -251A > T, no significant differ-
ence in the levels of immune markers was observed.
Synergism between the SNPs was also investigated. Pa-
tients carrying the combination of APEX1 148Glu/_ plus
IL8 -251 T/_ exhibited reduced levels (P < 0.05) of IL-1β
and MIP-1β/CCL4 (Fig. 2a). The combination of IL8 T/_
plus APEX1 Glu/_ plus AADAT T/_ also induced the re-
duction of cytokines TNF-α, MIP-1α/CCL3, and MIP-
1β/CCL4 (Fig. 2b) in CSF samples from BM patients. In
presence of the three variant alleles of the DNA repair
genes, a decrease (P < 0.05) in the levels of TNF-α, MIP-
1α/CCL3, MIP-1β/CCL4, and G-CSF in the CSF (Fig. 2c)
was observed. The other combinations did not demon-
strate significant changes in the concentrations of cyto/
chemokines (Additional file 1: Figures S3 and S4).
The relationships between the levels of these inflam-
matory modulators and cell counts in the CSF of BM
patients were also assessed in terms of genotypic combi-
nations. A significant reduction in cell count was ob-
served in patients with the combined genotype APEX1
148Glu/_ plus IL8 -251T/_ or APEX1 148Glu/_ plus
AADAT +401T/_ (Figs. 2d and e). Analysis of these com-
binations demonstrated significant correlations between
cell count and IL-1β, IL-6, TNF-α, MIP-1α/CCL3, MIP-
1β/CCL4 and G-CSF (Table 6). These data suggest a
possible synergism between the polymorphisms, given
that an additive effect in terms of reduced levels of in-
flammatory modulators was observed. Other genotypic
combinations did not achieve significance in terms of
cell count (Additional file 1: Figure S5).
Discussion
The genetic characteristics of patients are considered
important factors in BM occurrence [2–4]. In a previous
Fig. 1 Cytokine and chemokine concentrations in relation to the genotype for SNP TNF -308G > A. a CSF samples of BM patients. b Plasma
samples of controls. Legend: White Bar - cytokine levels for patients with ancestral genotype; Black bar - cytokine levels for patients with at least
one polymorphic allele. *Statistical significance (P < 0.05); # borderline values
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Fig. 2 Cyto/chemokine concentrations and cell counts in CSF in relation to the combination of genotypes in BM patients. a APEX1 148Glu/_ plus
IL8 -251 T/_ combination. b IL8 -251 T/_ plus APEX1 148 Glu/_ and AADAT +401 T/_ combination. c APEX1 148Glu/_ plus OGG1 326Cys/_ and
PARP1 l762Ala/_ combination. d Cell counts associated with the combined genotype APEX1 148Glu/_ plus IL8 -251 T/_. e Cell counts associated
with the combined genotype APEX1 148Glu/_ plus AADAT +401 T/_. *Statistical significance (P < 0.05)
Table 6 Correlation between cell count and cytokine and chemokine levels in CSF from BM patients in terms of genotypic
combinations
Genotypic combinations Cytokines and chemokines
APEX1 + 148 Asn/Asn plus IL8 -251 AA IL-1β IL-6 TNF-α MIP1-α MIP1-β MCP-1 G-CSF
Spearman r 0.428 0.305 0.391 0.204 0.422 −0.155 −0.037
P-value 0.047* 0.168 0.072 0.363 0.050* 0.490 0.870
APEX1 + 48Glu/_ plus IL8 -251 T/_ IL-1β IL-6 TNF-α MIP1-α MIP1-β MCP-1 G-CSF
Spearman r 0.830 0.547 0.781 0.735 0.791 0.346 0.788
P-value <0.001* 0.019* 0.0013* <0.001* <0.001* 0.159 <0.001*
APEX1 + 148 Asn/Asn plus AADAT + 401 CC IL-1β IL-6 TNF-α MIP1-α MIP1-β MCP-1 G-CSF
Spearman r 0.111 0.506 0.311 −0.100 0.032 −0.007 −0.104
P-value 0.673 0.038* 0.224 0.701 0.903 0.978 0.691
APEX1 + 148 Glu/_ plus AADAT +401 T/_ IL-1β IL-6 TNF-α MIP1-α MIP1-β MCP-1 G-CSF
Spearman r 0.783 0.623 0.579 0.507 0.645 0.060 0.625
P-value <0.001* 0.007* 0.005* 0.012* 0.005* 0.818 0.007*
*Significant P-value (P < 0.05). Correlation analysis was performed using a two-tailed Spearman test (cell count vs. cytokine or chemokine levels)
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study, we identified the association of the variant alleles
AADAT +401C > T and APEX1 Asn148Glu with the oc-
currence of BM. These SNPs were also shown to influ-
ence both the innate and adaptive immune responses
[12, 13]. In the present work, we analyzed the associ-
ation of SNPs in the TNF and IL-8 genes and investi-
gated the effects of combining all SNPs, including
previously published SNPs [12, 13]. The low frequency
of disease and the poor public health system in Natal
(Brazil) did not permit the recruitment of a large group
of patients for the study, but our sample size is in ac-
cordance with the epidemiological and clinical spectrum
of BM in our region [31, 32].
Systematic differences in ancestry between cases and
controls can be found when genetically distinct sub-
groups demonstrate differing prevalences of target phe-
notypes [33]. When heterogeneity is equivalent in cases
and controls (i.e., the two groups have the same mixture
of ethnic/genetic subgroups), stratification does not
occur, such as in admixed populations [34]. Although we
did not investigate ancestry in our samples, it is known
that the Brazilian population has great potential for re-
search due to its admixture, and the various combina-
tions of variants at different loci facilitates the study of
gene-gene interactions, which in other homogeneous
populations would not be possible. In our specific popu-
lation, samples were obtained from individuals from
northeastern Brazil, which has no specific ethnicity; in-
deed, this population has the highest degree of admix-
ture in Brazil [35].
Significant differences in the distribution of the indi-
vidual TNF -857C > T and IL8 -251A > T variant geno-
types between patients and healthy controls were not
found (Table 4). However, for the SNP TNF -308G > A, a
higher prevalence of the heterozygote in the control
group and the homozygote for the wild type allele in the
BM group (Table 4) was observed, suggesting a possible
protective role against the disease, which must be fur-
ther investigated. The genotypic frequencies found in
our work for SNP TNF -308G > A are similar to those
found in other populations [36–38].
Alterations in cytokine and chemokine profiles were
observed in the presence of the TNF -308A allele (Fig. 1).
Despite the fact that the P-value for TNF-α levels had a
borderline value, the biological relevance may be consid-
ered, as statistical significance was obtained for other cy-
tokines regulated by TNF-α. These data corroborate
previous work that reported the effect of the SNP TNF
-308G > A on TNF gene transcription [16, 17]. TNF-α is
one of the primary pro-inflammatory cytokines that
plays a central role in initiating and regulating the in-
flammatory response, acting as a mediator of resistance
to infectious agents, and therefore is important in host
defense. TNF-α is involved in the signal transduction
pathways that activate cellular NF-κB, which is a tran-
scription factor that regulates the expression of many
pro-inflammatory genes [39–41]. Furthermore, TNF-α is
indirectly related to the production of immunoglobulin
via TGF-β1 induction [42].
In several infection models, an inefficient immune re-
sponse by cytokines and chemokines was associated with
a decrease in the clearance of pathogens, the develop-
ment of invasive disease and high mortality [43–45].
Low levels of IL-1β, TNF-α or IL-6 in nasopharyngeal
secretions were observed in children with recurrent epi-
sodes of acute otitis media, an important cause of men-
ingitis [46]. These cytokines are important for the
activation of chemokines (such as MIP-1α/CCL3 and
MIP-1β/CCL4) involved in leukocyte recruitment to the
infection site for effective pathogen eradication [47].
However, the severity of meningococcal meningitis is
directly correlated with the production of IL-1β, TNF-α,
IL-6 and IL-8 [48, 49].
For complex diseases, the effect of an individual gene
is likely to be small and may be modulated by gene-gene
or gene-environment interactions [50]. Considering that
the pathophysiology of infectious disease involves the
interaction of several proteins and pathways, certain
genetic combinations suggest a risk factor for the occur-
rence of severe BM [3, 4]. In this work, certain genotypic
combinations were prevalent in BM patients. After ana-
lyzing the genotype distributions of the SNP combina-
tions between cases and controls, we found that there
were five genotypic combinations that exhibited the
highest frequencies in the BM patient group compared
to the control group, particularly the IL-8T/_, APEX1
Glu/_, OGG1 Cys/_, PARP1 Ala/_, and AADAT T/_ ge-
notypes (Table 5). This indicated that interaction of
these five SNPs may result in the occurrence of BM. The
combination of the wild type genotype of the TNF gene
(GG) with the variant alleles AADAT T/_, APEX1 Glu/_,
and IL8 T/_ also resulted in statistical significance.
In contrast to the other SNPs analyzed, the combin-
ation of the two variant alleles of the TNF gene exhibited
an interesting additive effect in the control group. Indi-
vidually, the SNP TNF -857C > T frequency did not sug-
gest an association with BM, as there were no
differences between BM and the control group. How-
ever, in the control group, the frequency of both the
variant TNF -857T and TNF -308A alleles was higher
than the BM group, suggesting a possible protective role
against infection. However, further studies are needed to
confirm this hypothesis.
Analysis of the combined effects of SNPs in compari-
son to the levels of inflammatory modulators also dem-
onstrated significant associations that may contribute to
the increased risk for BM occurrence. A synergistic
effect in cytokine and chemokine expression was
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observed for some genetic combinations. The SNPs
APEX1 Asn148Glu, PARP1 Val762Ala and OGG1
Ser326Cys were previously described to be involved in
the reduction of DNA repair function [13, 51–53]. In
this study, the presence of variant alleles of DNA repair
genes was associated with a reduction in the levels of
TNF-α, MIP-1α/CCL3, MIP-1β/CCL4 and G-CSF, sug-
gesting a less active inflammatory response in patients
who possess this combination.
APE1 and PARP-1 were initially known as DNA repair
enzymes but are also important activators and co-factors
of the DNA-binding activity of NF-κB and AP-1 (activa-
tor protein1) [54–59], which are master regulators of the
inflammatory response [41, 59]. In addition, these two
enzymes may contribute to the regulation of humoral
immunity by participating in immunoglobulin class
switch recombination [60, 61].
In inflammation models such as endotoxic shock, dia-
betes and contact hypersensitivity, OGG1 gene knockout
in mice was shown to be associated with decreased
serum cytokine and chemokine levels, which highlights
the importance of this enzyme in the inflammatory re-
sponse [62].
In addition to the role of DNA repair enzymes in the
activation of NF-κB and AP-1, some work has proposed
a role for the BER pathway in transcriptional activation,
although the mechanisms involved are not well under-
stood. The occurrence of oxidized bases in promoter
regions may affect the binding properties of transcrip-
tional factors such as AP-1 [63] or interfere with CpG is-
land methylation, an event that commonly suppresses
gene transcription [64]. Recently, Khobta et al. [65] ob-
tained data showing that oxidized bases induce gene si-
lencing in a potential chromatin-mediated mechanism
associated with a decrease in histone H4 acetylation in
the promoter region. In addition, the demethylation ac-
tivity mediated by the LSD1 enzyme produces H2O2,
which locally oxidizes guanine and induces the recruit-
ment of OGG1 and APE1, which are involved in the
chromatin remodeling that is necessary for transcrip-
tional activation of the target genes [66]. Based on these
studies, polymorphisms in DNA repair enzymes may
generate aberrant gene expression, triggering changes in
the inflammatory response.
IL-8/CXCL8 is an important mediator that has been
implicated in biochemical pathways involved in a wide
range of inflammatory diseases [19–21, 67–69]. Activa-
tion of CXCL8/IL8 in gastric epithelial cells infected
with H. pylori is directly dependent on the activation of
AP-1, which is regulated by APE1. The silencing of
APE1 expression by siRNA causes a reduction in H. pyl-
ori-induced IL-8 mRNA and protein, supporting the hy-
pothesis that APE1 is involved in the control of gene
expression in bacterial pathogenesis [69]. Although the
SNP IL8 -251A > T was not related to BM occurrence,
combination with the variant allele APEX1 148Glu re-
sulted in statistical significance (Table 5). The analysis of
immune markers provides evidence that these polymor-
phisms may exhibit synergism, as a reduction in cyto-
kine and chemokine levels and in cell counts was
observed (Fig. 2).
Activation of the KYN pathway was observed during the
acute phase of pneumococcal meningitis in infant rats
[70]. In a previous study, we also found an association be-
tween the kynurenine aminotransferase II gene C401T
polymorphism (SNP AADAT +401C > T) and BM occur-
rence [12]. Recently, we observed that this polymorphism
is associated with an increase in kynurenic acid (KYNA)
levels [22], which has anti-inflammatory effects, as it is in-
volved in modulating the immune responses mediated by
activation of G protein-coupled receptor 35 (GPR35) [71].
This may explain the lower levels of cyto/chemokines and
cell counts observed in patients carrying the T allele.
The role of chemokines in regulating leukocyte re-
cruitment during infection has also been reported
[45, 72, 73]. We observed a significant correlation
(P < 0.05) between cell counts and IL-1β, IL-6, TNF-
α, MIP1-α, MIP1-β and G-CSF levels in BM patients
who had genotypic combinations involving the alleles
APEX1 148Glu, IL8 -251T and AADAT +401T (Table 6),
suggesting a reduced capacity for leukocyte recruitment in
these patients.
During the BM acute phase, an increase occurs in the
expression of some cytokines, such as TNF-α and IL-6,
which is useful for differential diagnosis with regard to
other meningitis types such as aseptic or chronic menin-
gitis [74–76]. As our biological samples intended for the
measurement of inflammatory modulators were col-
lected in the acute phase of the disease and the results
of the genotype comparisons with reference to cytokine
and chemokine levels were not significantly influenced
by the time of collection.
Conclusions
In conclusion, analysis of individual polymorphisms sug-
gested that the TNF -308A allele may play a potential
role in protecting against BM. In addition, genetic com-
binations, primarily involving the TNF -308G, APEX1
148Glu, IL8 -251T and AADAT +401T alleles, were
shown to be associated with the inflammatory process in
general, leading to decreased expression of cyto/chemo-
kines. This may be related to a reduced ability to
eradicate the pathogen and consequent susceptibility to
disease. In this paper, we proposed a possible model for
gene-gene interactions between important pathways that
are activated during BM. However, the low number of
patients is a limitation of our work; therefore, collabora-
tive studies conducted in different populations are
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necessary to corroborate our findings. Our data indicate
that an extensive evaluation of the variability of these
genes may contribute to a better understanding of sus-
ceptibility to BM and potentially to other infectious or
inflammatory diseases. This knowledge will not only per-
mit clinical interventions but also the implementation of
programs for health promotion and disease prevention
directed towards susceptible individuals based on their
genomic profile, which may lead to decreased morbidity
and mortality through risk assessment and improvement
of the administration of prophylactic therapies.
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